Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company plc    PRGO   IE00BGH1M568


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Perrigo : Advances Consumer Self-Care Growth Strategy with Acquisition of Prevacid24HR

share with twitter share with LinkedIn share with facebook
share via e-mail
09/06/2019 | 10:22am EST

Dublin - Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a definitive agreement to acquire the branded OTC rights to Prevacid from GlaxoSmithKline.

Under the terms of the agreement, Perrigo will have the exclusive rights to market, sell and distribute Prevacid24HR in the United States OTC market. Financial terms of the agreement were not disclosed.

Prevacid24HR treats frequent heartburn (occurring 2 or more days a week) and is not intended for immediate relief of heartburn.

Perrigo CEO and President Murray S. Kessler commented, 'This acquisition of the well-established brand Prevacid24HR is another example of how tuck-in acquisitions can expand our robust self-care portfolio. This margin accretive asset strengthens our leadership position in a core category and is expected to accelerate brand and category growth. I am confident our team can enhance the value of the Prevacid brand. Perrigo is in the unique position to leverage its 1) existing infrastructure and manufacturing expertise as we currently promote the active ingredient lansoprazole as a store brand product, 2) expansive U.S. customer network, and 3) innovation pipeline in the gastrointestinal category, which extends beyond current national brand offerings.'

About Perrigo

Perrigo Company plc (NYSE; TASE: PRGO) is dedicated to making lives better by bringing 'Quality, Affordable Self-care Products' that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

Forward-Looking Statements

Certain statements in this press release are 'forward-looking statements.' These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'forecast,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'potential' or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company's appeal of the Notice of Assessment ('NoA') issued by the Irish tax authority and the Notice of Proposed Adjustment ('NOPA') issued by the U.S. Internal Revenue Service and the impact that an adverse result in such proceedings would have on operating results, cash flows, and liquidity; potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information and litigation relating to uncertain tax positions, including the NoA and NOPA; potential impacts of ongoing or future government investigations and regulatory initiatives; the impact of tax reform legislation and healthcare policy; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions and the success of such transactions, and the Company's ability to realize the desired benefits thereof and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic and other initiatives. Statements regarding the separation of the RX business, including the expected benefits, anticipated timing, form of any such separation and whether the separation ultimately occurs, are all subject to various risks and uncertainties, including future financial and operating results, our ability to separate the business, the effect of existing interdependencies with our manufacturing and shared service operations, and the tax consequences of the planned separation to the Company or its shareholders. Furthermore, the Company may incur additional tax liabilities in respect of 2016 and prior years or be found to have breached certain provisions of Irish company law in connection with the Company's restatement of previously-filed financial statements, which may result in additional expenses and penalties. These and other important factors, including those discussed under 'Risk Factors' in the Company's Form 10-K for the year ended December 31, 2018, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Bradley Joseph

Tel: (269) 686-3373

Email: bradley.joseph@perrigo.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
01/14PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
01/07PERRIGO : Advances Consumer Self-Care Growth Strategy with Ranir Subsidiary Acqu..
2019PERRIGO : Donates a Total of $75,000 to Wings of Hope Hospice and Wings Home
2019PERRIGO : Announces Closing of Prevacid24HR Acquisition, Advancing Consumer Self..
2019PERRIGO COMPANY PLC : Ex-dividend day for
2019PERRIGO : Donates Building Appraised at $320,000 to Safe Harbor to Protect Child..
2019PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
2019PERRIGO : 3Q Earnings Snapshot
2019PERRIGO : Ranitidine - MHRA drug alerts issued as Perrigo recalls prescription o..
More news
Financials (USD)
Sales 2019 4 813 M
EBIT 2019 812 M
Net income 2019 272 M
Debt 2019 2 892 M
Yield 2019 1,40%
P/E ratio 2019 28,4x
P/E ratio 2020 18,3x
EV / Sales2019 2,23x
EV / Sales2020 2,07x
Capitalization 7 855 M
Duration : Period :
Perrigo Company plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 14
Average target price 59,08  $
Last Close Price 57,71  $
Spread / Highest target 21,3%
Spread / Average Target 2,38%
Spread / Lowest Target -8,16%
EPS Revisions
Murray S. Kessler President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Ronald Janish Executive VP-Global Operations and Supply Chain
Raymond P. Silcock Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.92%395 123
ROCHE HOLDING AG9.79%294 912
NOVARTIS4.27%220 633
MERCK AND COMPANY-9.13%210 426
PFIZER-5.74%202 051